PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to ...

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 ...

PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections ...

D-PLEX100 plus SoC reduced infection ... abdominal colorectal surgeries with large incisions. The trial’s primary endpoint is measured by the proportion of subjects with a surgical site ...

Preoperative antibiotics do not lower perforation rates in uncomplicated acute appendicitis but do lower postop infection ...

Investors reacted positively to the robust data, which PolyPid believes will accelerate global partnership discussions. The company also emphasized the absence of safety concerns raised by the ...

Fry, M.D.: That is also the dependent part of the abdominal wall closure ... Let's talk about some of the complexities of surgical site infection (SSI) clinical trials. There are problems of ...

Fintel reports that on June 5, 2025, Roth Capital initiated coverage of PolyPid (NasdaqCM:PYPD) with a Buy recommendation. Analyst Price Forecast Suggests 264.09% Upside As of June 2, 2025, the ...

This is the most common form of hernia and occurs in the groin area. Your chances of getting this type of hernia go up with ...

So Diplex one hundred takes the Plex platform and combines it with doxycycline, which is a known broad spectrum antibiotic approved many years on the market, safe, with a with a target of preventing ...